Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives.
This publication is a narrative review on cancer vaccines in lung cancer, focused on overcoming resistance to immune che...
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer.
- Post category:Respiratory (Lung, Bronchus) System
- Reading time:1 min read
This publication describes the creation of the APOLLO11 consortium, a nationwide Italian network focused on lung cancer,...
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.
- Post category:Respiratory (Lung, Bronchus) System
- Reading time:1 min read
Phase III TASUKI-52: 4-year outcomes Population & design - Untreated advanced nonsquamous NSCLC. - Randomized 1:1 t...
First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options-A Podcast.
- Post category:Respiratory (Lung, Bronchus) System
- Reading time:2 mins read
This publication is a podcast-style discussion on current management of metastatic ALK‑positive NSCLC, with an emphasi...
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII).
- Post category:Respiratory (Lung, Bronchus) System
- Reading time:2 mins read
This phase III randomized superiority trial compared ultra-low-dose nivolumab with standard single-agent chemotherapy (d...
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.
- Post category:Respiratory (Lung, Bronchus) System
- Reading time:2 mins read
This phase 2, multicenter, open-label trial (FMT-LUMINate; NCT04951583) evaluated whether a single fecal microbiota tran...